Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 2

A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

NCT06985147 · View on ClinicalTrials.gov ↗

Study Summary

This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).

Conditions Studied

Interventions

  • DRUG DISC-3405

Study Locations (14)

California

  • USC Norris Comprehensive Cancer Center — Los Angeles
  • UCLA Health — Los Angeles
  • Keck Medicine of USC - Cancer Clinic- Newport Beach — Newport Beach

North Carolina

  • Atrium Health - Levine Cancer Center — Charlotte
  • Duke University — Durham
  • Atrium Health Wake Forest Baptist Medical Center — Winston-Salem

Arizona

  • Mayo Clinic in Arizona — Phoenix

Florida

  • Mayo Clinic in Florida — Jacksonville

Minnesota

  • Mayo Clinic in Minnesota — Rochester

Missouri

  • Siteman Cancer Center - Washington University St. Louis — St Louis

Ohio

  • Ohio State University — Columbus

Oregon

  • Oregon Health & Science University — Portland

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-08-12
Est. Completion 2029-02
Phase Phase 2

Sponsor

Disc Medicine

60 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06985147

The ClinicalTrials.gov registry entry for NCT06985147 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Disc Medicine, which has 60 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Polycythemia Vera (PV) appearing as the primary indexed condition, and to 1 intervention — of which DISC-3405 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06985147 reports 14 study locations spanning 10 distinct geographic areas — top geographies include California, North Carolina, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06985147 about?

NCT06985147 is a clinical study titled "A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)". This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).

What is the current status of trial NCT06985147?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-08-12. Estimated completion is 2029-02.

What conditions does trial NCT06985147 study?

This clinical trial studies the following conditions: Polycythemia Vera (PV). These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06985147?

The interventions under investigation include: DISC-3405 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06985147?

This trial is sponsored by Disc Medicine, which has 60 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06985147 being conducted?

This trial has 14 study locations across Arizona, California, Florida, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial